Key takeaways
- Researchers argue that relying solely on GLP-1 drugs medicalizes obesity while ignoring the systemic impact of ultra-processed foods.
- A systems analysis shows that treating obesity as a personal responsibility remains the biggest barrier to solving the epidemic.
- Advocates call for tobacco-style regulations on food, such as marketing curbs, taxation, and warning labels, to run alongside clinical treatments.
What happened
In a perspective article published in Science, prominent health policy researchers argued that the rise of the "Ozempic era" must be paired with aggressive, tobacco-style food regulations. Laura Schmidt, PhD, of the University of California San Francisco, and Luc Hagenaars, PhD, of the Amsterdam University Medical Center, warned that relying solely on GLP-1 medications to treat obesity medicalizes a systemic problem while ignoring the ultra-processed food environment driving the epidemic.
Why it matters
For millions of US consumers, the skyrocketing popularity of weight-loss medications has shifted the clinical focus toward individual treatment, often accessed via cash-pay telehealth platforms. However, researchers point out that treating obesity purely as an individual medical condition overlooks how heavily engineered, ultra-processed foods cause overeating. Without systemic reforms—such as marketing restrictions, warning labels, and taxes on ultra-processed products—relying on expensive medications risks exacerbating health disparities, particularly as commercial interests drive these drugs primarily toward higher-income populations.
What the data says
The researchers' argument is grounded in a systems analysis conducted by Schmidt and Hagenaars, which identified the belief that obesity is solely an individual's responsibility as the single largest obstacle to resolving the crisis.
Clinical trial data cited by the authors confirms that ultra-processed foods directly cause obesity by inducing people to consume more calories than they would on an unprocessed diet. While GLP-1 receptor agonists are highly effective at treating established cardiometabolic disease, the World Health Organization (WHO) has raised concerns about the equitable distribution of these therapies. Currently, pharmaceutical, food, and supplement companies are capitalizing on the GLP-1 boom, channeling these expensive therapies almost exclusively toward wealthy demographics and high-income nations.
How it compares
The debate over systemic food policy versus medical treatment highlights a critical tension for patients evaluating their options. Currently, brand-name GLP-1 medications like Wegovy and Zepbound carry US list prices exceeding $1,000 per month. Because commercial insurance coverage remains highly restrictive, many patients turn to online providers listed on our comprehensive provider directory to compare options.
Many of these buyers choose to compare out-of-pocket costs and seek alternative treatments, such as compounded semaglutide or tirzepatide, which typically range from $200 to $400 per month. However, the researchers emphasize that while these clinical options are vital for individuals with active metabolic disease, they do not address the root environmental causes. Comparing medical treatment to public health prevention, Schmidt argues that both must coexist: medications should support those currently suffering, while regulatory reforms prevent metabolic disease from developing in the first place.
How this fits the bigger picture
This policy debate reflects a broader pattern of rising clinical demand meeting systemic healthcare barriers. As employers scale back coverage due to unsustainable costs—a trend we explored in our coverage of how employers are overhauling GLP-1 benefits—more patients are forced to seek cash-pay telehealth options.
The pressure on the clinical system is also driving unprecedented expansions in how these drugs are prescribed. We have previously reported on how GLP-1 prescriptions have surged 500% among patients with serious mental illness, highlighting the expanding clinical footprint of these therapies. At the same time, the push to medicalize obesity early in life is reflected in our report on how off-label GLP-1 prescriptions for children under 12 have surged 310-fold.
These trends reinforce the researchers' warnings: as clinical interventions reach younger and broader populations, the underlying food environment remains completely unchanged, leaving the true root cause of the epidemic unaddressed.
What happens next
Moving forward, the World Health Organization faces the difficult task of advocating for global regulatory reforms while promoting the equitable distribution of metabolic treatments. Public health advocates will continue pushing for policy measures modeled on tobacco control, such as strict limits on marketing targeted at children, warning labels on ultra-processed foods, and school-based nutritional interventions.
In the meantime, US buyers will continue to navigate a commercialized telehealth market. Patients can use resources like our questionnaire and educational guides to learn how we rank clinical programs and find affordable, safe pathways to care.
CompareRx is a consumer information research platform and newsroom. The contents of this article are for informational purposes only and do not constitute medical advice.